References
- Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral rennin inhibitor, provides dose-dependent efficiency and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997–1005
- Ogihara T, Kikuchi K, Matsuoka H, et al., On Behalf of The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3–107
- Martin T, Marcus G, Walter Z. Efficacy and tolerability of angiotensin II type1 receptor antagonists in dialysis patients using AN69 dialysis members. Kidney Blood Press Res 2001;24:71–4
- Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effect of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type2 patients on recent onset hemodialysis patient. Ther Apher Dial 2004;8:320–7
- Morishita Y, Hanawa S, Chinda J, et al. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 2011;34:308–13
- Morishita Y, Kusano E. The antihypertensive effect and organ protection of direct renin inhibitor (aliskiren) in dialysis patients with hypertension (in Japanese). The 33rd annual scientific meeting of the Japanese Society of Hypertension. Hakata, Japan, 15–17 October 2010
- Ruilope L, Kjeldsen SE, De La Sierra A, et al. The kidney and cardiovascular risk-implications for management: a consensus statement from European Society of Hypertension. Blood Press 2007;16:72–9
- Ram CV. Direct rennin inhibitor: a new approach to antihypertensive drug treatment. J Clin Hypertens (Greenwich) 2007;9:615–21
- Nagai H, Kanadu K, Kobori Y, et al. Plasma renin activity in hemodialysis patients. Jinko-Tosekikenkyuukaikaishi 1978;1:385–6 (Japanese)
- Teranishi M, Miyashita K, Suzuki M, et al. Clinical significance of post-dialysis plasma concentrations of atrial natriuretic peptide and brain natriuretic peptide as long-term survival predictors in hemodialysis patients: 15-year follow up study. Dokkyo J Med Sci 2008;35:71–8 (Japanese, Abstract in English)
- McMurray JJ, Pitt B, Latini R, et al., Aliskiren Observation of Heart Failure Treatment Investigatores. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17–24
- Moist L. Review: aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone. Ann Intern Med 2012;156:JC6–9
- Liu Y, Chen K, Kou X, et al. Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One 2013;8:e70111
- European Medical Agency. Questions and answers on the review aliskiren-containing medicines. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/02/WC500122916.pdf Updated 16 Feb 2012 [last accessed 11 Dec 2012]